Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Net Cash Flow (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Net Cash Flow data on record, last reported at $1.4 million in Q4 2025.

  • For Q4 2025, Net Cash Flow fell 77.69% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $147.7 million, up 261.19%, while the annual FY2025 figure was $147.7 million, 261.19% up from the prior year.
  • Net Cash Flow reached $1.4 million in Q4 2025 per AMLX's latest filing, down from $166.5 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $166.5 million in Q3 2025 and bottomed at -$112.4 million in Q3 2023.
  • Average Net Cash Flow over 5 years is $10.7 million, with a median of $909000.0 recorded in 2024.
  • The widest YoY moves for Net Cash Flow: up 6325.65% in 2025, down 3965.73% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$26.5 million in 2021, then crashed by 72.54% to -$45.7 million in 2022, then surged by 175.92% to $34.7 million in 2023, then tumbled by 82.48% to $6.1 million in 2024, then tumbled by 77.69% to $1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $1.4 million in Q4 2025, $166.5 million in Q3 2025, and -$2.3 million in Q2 2025.